Skip to content

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Frederick S Barrett, Matthew W Johnson, Roland R Griffiths

Journal of Psychopharmacology October 6, 2015 DOI: 10.1177/0269881115609019 via OpenAlex

Summary

AI-generated from the abstract

The 30-item revised Mystical Experience Questionnaire (MEQ30) is validated using data from five controlled laboratory experiments with psilocybin. Participants (n=184) received a moderate to high oral dose of psilocybin (at least 20 mg/70 kg). Confirmatory factor analysis shows the MEQ30 is reliable and internally valid. Structural equation models demonstrate external and convergent validity: latent variable scores on the MEQ30 positively predict persisting changes in attitudes, behavior, and well-being attributed to psilocybin experiences, beyond the participant-rated intensity of drug effects. The findings support the MEQ30 as an efficient measure of individual mystical experiences. A method to score a "complete mystical experience" from previous versions is validated, and a stand-alone MEQ30 is provided.

Study at a glance

Characteristics Validation study using pooled data from five laboratory experiments Peer reviewed
Sample size 184
Population Participants in controlled laboratory experiments receiving a moderate to high oral dose of psilocybin
Intervention psilocybin
Dose at least 20 mg/70 kg
Topics Mysticism Psilocybin
Keywords Structural equation modeling Hallucinogen Confirmatory factor analysis
Citations 634
Key finding The MEQ30 is a reliable and valid measure of mystical-type experiences, and its scores positively predict persisting changes in attitudes, behavior, and well-being attributed to psilocybin experiences.

Abstract

The 30-item revised Mystical Experience Questionnaire (MEQ30) was previously developed within an online survey of mystical-type experiences occasioned by psilocybin-containing mushrooms. The rated experiences occurred on average eight years before completion of the questionnaire. The current paper validates the MEQ30 using data from experimental studies with controlled doses of psilocybin. Data were pooled and analyzed from five laboratory experiments in which participants ( n=184) received a moderate to high oral dose of psilocybin (at least 20 mg/70 kg). Results of confirmatory factor analysis demonstrate the reliability and internal validity of the MEQ30. Structural equation models demonstrate the external and convergent validity of the MEQ30 by showing that latent variable scores on the MEQ30 positively predict persisting change in attitudes, behavior, and well-being attributed to experiences with psilocybin while controlling for the contribution of the participant-rated intensity of drug effects. These findings support the use of the MEQ30 as an efficient measure of individual mystical experiences. A method to score a “complete mystical experience” that was used in previous versions of the mystical experience questionnaire is validated in the MEQ30, and a stand-alone version of the MEQ30 is provided for use in future research.

Explore topics

Comments

No comments yet.

Log in to comment